Brokerages Set Pediatrix Medical Group, Inc. (NYSE:MD) PT at $16.42

Pediatrix Medical Group, Inc. (NYSE:MD) has been given an average recommendation of “Hold” by the six brokerages that are covering the stock, Marketbeat reports. Four analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $16.42.

Several brokerages have commented on MD. Truist Financial upped their price target on Pediatrix Medical Group from $13.00 to $16.00 and gave the stock a “hold” rating in a research note on Monday, November 4th. Deutsche Bank Aktiengesellschaft raised their price target on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the company a “hold” rating in a report on Monday, November 4th. Macquarie started coverage on shares of Pediatrix Medical Group in a research note on Monday, December 16th. They set an “outperform” rating and a $18.00 price objective for the company. UBS Group increased their price objective on shares of Pediatrix Medical Group from $10.50 to $16.50 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Finally, Mizuho lifted their target price on shares of Pediatrix Medical Group from $13.00 to $15.00 and gave the company a “neutral” rating in a report on Tuesday, November 19th.

Insider Buying and Selling

In other Pediatrix Medical Group news, EVP Mary Ann E. Moore sold 8,108 shares of the company’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $16.00, for a total value of $129,728.00. Following the transaction, the executive vice president now directly owns 135,810 shares of the company’s stock, valued at $2,172,960. This represents a 5.63 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Mark S. Ordan sold 27,600 shares of the stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total value of $423,660.00. Following the transaction, the director now owns 138,683 shares of the company’s stock, valued at approximately $2,128,784.05. This trade represents a 16.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Pediatrix Medical Group

Several hedge funds and other institutional investors have recently modified their holdings of MD. nVerses Capital LLC bought a new stake in Pediatrix Medical Group in the second quarter valued at about $31,000. Quest Partners LLC increased its holdings in shares of Pediatrix Medical Group by 25.6% in the 3rd quarter. Quest Partners LLC now owns 3,054 shares of the company’s stock valued at $35,000 after acquiring an additional 622 shares during the last quarter. Quarry LP raised its position in shares of Pediatrix Medical Group by 54.1% during the 3rd quarter. Quarry LP now owns 4,735 shares of the company’s stock valued at $55,000 after acquiring an additional 1,662 shares in the last quarter. Canada Pension Plan Investment Board bought a new position in Pediatrix Medical Group during the second quarter worth $72,000. Finally, CWM LLC boosted its holdings in Pediatrix Medical Group by 134.0% in the third quarter. CWM LLC now owns 6,427 shares of the company’s stock worth $74,000 after purchasing an additional 3,681 shares during the period. Institutional investors own 97.71% of the company’s stock.

Pediatrix Medical Group Trading Up 0.8 %

Shares of MD stock opened at $13.14 on Tuesday. Pediatrix Medical Group has a 1-year low of $6.62 and a 1-year high of $16.41. The firm’s 50-day simple moving average is $14.35 and its 200-day simple moving average is $11.43. The firm has a market cap of $1.13 billion, a P/E ratio of -4.29, a PEG ratio of 2.00 and a beta of 1.58. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.42 and a quick ratio of 1.42.

Pediatrix Medical Group (NYSE:MD) last announced its quarterly earnings results on Friday, November 1st. The company reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.37 by $0.07. The company had revenue of $511.20 million for the quarter, compared to analyst estimates of $498.87 million. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. Pediatrix Medical Group’s revenue for the quarter was up .9% on a year-over-year basis. During the same quarter last year, the business earned $0.29 EPS. As a group, equities analysts forecast that Pediatrix Medical Group will post 1.26 EPS for the current year.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.